In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Pharvaris, with a price target of $43.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on the promising outlook for Pharvaris’s drug, deucrictibant, in treating hereditary angioedema (HAE). The company has updated its timeline for the drug’s on-demand program, with a Phase 3 study expected to yield results in the fourth quarter of 2025, earlier than previously anticipated. This accelerated timeline suggests a potential for strong efficacy, which could enhance the drug’s market position despite competition from existing treatments.
Additionally, the upcoming launches of several HAE treatments are likely to increase market interest, potentially benefiting Pharvaris’s visibility. The anticipated results from another Phase 3 study for a prophylactic use of deucrictibant in the second half of 2026 could further strengthen its market potential. Given the current stock levels, Chatterjee sees this as an opportune moment for investment, reinforcing the Buy recommendation.
In another report released on June 30, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.